Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Axl


Brief Information

Name:AXL receptor tyrosine kinase
Target Synonym:EC:,EC 2.7.10,UFO,AXL Transforming Sequence/Gene,AXL Oncogene,EC,JTK11,Tyro7,ARK,Tyrosine-protein kinase receptor UFO,AXL,AXL Receptor Tyrosine Kinase
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Biotinylated Human AXL, Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human AXL, Fc,Avitag (Cat. No. AXL-H82F9) is more than 90% and the molecular weight of this protein is around 155-185 kDa verified by SEC-MALS.

Biotinylated Human AXL, Fc,AvitagBiotinylated Human AXL, Fc,Avitag (Cat. No. AXL-H82F9) ELISA bioactivity

Immobilized Human GAS6, His Tag (Cat. No. GA6-H5249) at 5 μg/mL (100 μL/well) can bind Biotinylated Human AXL, Fc,Avitag (Cat. No. AXL-H82F9) with a linear range of 1-31 ng/mL (QC tested).

Human Axl, Fc Tag (Cat. No. ) MALS images

The purity of Human Axl, Fc Tag (Cat. No. AXL-H5253) is more than 90% and the molecular weight of this protein is around 165-200 kDa verified by SEC-MALS.

Synonym Name



AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Thyroid Neoplasms; Adenocarcinoma, Follicular; Brain Neoplasms; Sarcoma; Neuroblastoma; Neurofibroma, Plexiform; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Bile Duct Neoplasms; Central Nervous System Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Thyroid Cancer, Papillary; Meningioma; Carcinoma, Transitional Cell; Kidney Neoplasms; Ovarian germ cell tumor; Bone metastases; Carcinoma, Renal Cell; Rejection of liver transplantation; Esophageal Neoplasms; Pain; Stomach Neoplasms; Carcinoma, Merkel Cell; Glioblastoma; Seminoma; Solid tumours; Neurofibromatoses; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Papillary; Skin Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Adrenocortical Carcinoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma Details
Gilteritinib Fumarate ASP-2215; 66D-92MGC8M (UNII code); ASP-2215 hemifumarate Approved Astellas Pharma Inc Xospata Mainland China Leukemia, Myeloid, Acute Astellas Pharmaceutical (China) Co Ltd 2018-09-21 Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms Details
AGX-0073 AGX-0073 Phase 1 Clinical Shanghai Aojian Biological Technology Co Ltd Solid tumours Details
NP-107 NP107; NP-107 Phase 1 Clinical Shanghai Nawei Biotechnology Co Ltd Solid tumours Details
Butylidenephthalide NSC-325307; BDPH; HK-001 Everfront Biotech Co Ltd Details
XZB-0004 SLC-391; XZB-0004 Phase 1 Clinical Solid tumours; Hematologic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CCT301-38 CCT301-38; CCT301-38 AXL F1 Oncology, Bioatla Details
Enapotamab vedotin AXL-107-MMAE Seattle Genetics Inc, Genmab Details
KC1036 KC1036; KC-1036 Phase 2 Clinical Beijing Konruns Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasm Metastasis Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Mirati Therapeutics Details
BPI-9016 BPI-9016; BPI-9016M Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
RXDX-106 RXDX-106 Teva, Daiichi Sankyo Co Ltd Details
INCB-081776 INCB-81776; INCB-081776 Incyte Corp Details
ONO-7475 ONO-7475 Phase 2 Clinical Ono Pharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
Dubermatinib TP-0903 Sumitomo Dainippon Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 1 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Q-702 Q-702 Phase 2 Clinical Qurient Co Ltd Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
PF-07265807 PF-07265807 Phase 1 Clinical Solid tumours; Neoplasm Metastasis Details
Mecbotamab vedotin BA-3011; BA3011; BA 3011 Phase 2 Clinical Bioatla Ovarian Neoplasms; Leiomyosarcoma; Solid tumours; Sarcoma, Synovial; Liposarcoma; Osteosarcoma; Sarcoma, Ewing; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Mipasetamab uzoptirine ADCT-601; BGB-601 Phase 1 Clinical Adc Therapeutics Solid tumours; Neoplasms Details
Tilvestamab BGB-149 Phase 1 Clinical Bergenbio Ovarian Neoplasms Details
Bemcentinib R-428; BGB-324 Phase 2 Clinical Rigel Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19); Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Adenocarcinoma of Lung; Pancreatic Neoplasms; Mesothelioma; Central Nervous System Neoplasms; Brain Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HH-30134 HH-30134 Phase 1 Clinical ShangHai HaiHe Biopharma Co Ltd Solid tumours; Neoplasms Details
TT-00973 TT-00973 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message